Abstract
Cyclooxygenase-2 (COX-2) inhibitors cause growth inhibition of human gastric carcinoma cells, but it remains unclear whether this is both COX-2 dependent and independent. The related mechanisms remain to be determined. Both low COX-2 expressing gastric carcinoma and high COX-2 expressing gastric carcinoma cells were used to study the effect and mechanisms of celecoxib on gastric carcinoma cell growth. Celecoxib resulted in comparable growth inhibition in AGS cells with stable transfections of small interfering RNA (siRNA) against COX-2 (SAC) and negative control vector (NC) cells. Simultaneously, celecoxib resulted in significant reduction of Bcl-2 and significant increase of p21WAF1 and p27KIP1 in SAC and NC cells. The present study shows that celecoxib causes growth inhibition of gastric carcinoma cells by decreasing Bcl-2 of cyclooxygenase-2-dependent pathway, and by increasing p21WAF1 and p27KIP1 of cyclooxygenase-2-independent pathway. These data extend our knowledge on the effect and mechanisms of celecoxib-induced inhibition of gastric carcinoma cell growth.
Similar content being viewed by others
References
Cuccurullo C, Fazia ML, Mezzetti A, Cipollone F. COX-2 expression in atherosclerosis: the good, the bad or the ugly? Curr Med Chem. 2007;14:1595–1605. doi:10.2174/092986707780830998.
Brock TG, Peters-Golden M. Activation and regulation of cellular eicosanoid biosynthesis. ScientificWorld Journal. 2007;7:1273–1284. doi:10.1100/tsw.2007.180.
Amir M, Agarwal HK. Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie. 2005;60:563–570.
Bertagnolli MM. Cox-2 and cancer chemoprevention: picking up the pieces. Recent results in cancer research. Fortschr Krebsforschung. 2007;174:73–78.
Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem. 2007;7:599–608. doi:10.2174/138955707780859431.
Nardone G, Rocco A. Chemoprevention of gastric cancer: role of COX-2 inhibitors and other agents. Dig Dis. 2004;22:320–326. doi:10.1159/000083593.
Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem. 2007;42:93–126. doi:10.1007/1-4020-5688-5_4.
Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55–80. doi:10.1146/annurev.pharmtox.42.082301.164620.
Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs. 2002;13:127–137. doi:10.1097/00001813-200202000-00003.
Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer. 2007;97:1523–1531. doi:10.1038/sj.bjc.6604057.
Shin VY, Wu WK, Chu KM, et al. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol Cancer Res. 2005;3:607–615. doi:10.1158/1541-7786.MCR-05-0106.
Da MX, Wu XT, Wang J, et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res. 2008;39:92–99. doi:10.1016/j.arcmed.2007.06.021.
Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol. 2004;67:1469–1478. doi:10.1016/j.bcp.2003.12.014.
Park JH, Kang KH, Kim SH, et al. Expression of Cyclooxygenase-2 and Bcl-2 in human gastric adenomas. Korean J Intern Med. 2005;20:198–204.
Liu XP, Tsushimi K, Tsushimi M, et al. Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett. 2001;170:183–189. doi:10.1016/S0304-3835(01)00589-4.
Belletti B, Nicoloso MS, Schiappacassi M, et al. p27 (kip1) functional regulation in human cancer: a potential target for therapeutic designs. Curr Med Chem. 2005;12:1589–1605. doi:10.2174/0929867054367149.
Wallace JM. Nutritional and botanical modulation of the inflammatory cascade—eicosanoids, cyclooxygenases, and lipoxygenases—as an adjunct in cancer therapy. Integr Cancer Ther. 2002;1:7–37. (discussion 37).
Kakizoe T. Chemoprevention of cancer–focusing on clinical trials. Jpn J Clin Oncol. 2003;33:421–442. doi:10.1093/jjco/hyg090.
Shin SS, Byun Y, Lim KM, et al. In vitro structure–activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2, 2-dialkyl-4-phenyl-3(2H)furanone derivatives. J Med Chem. 2004;47:792–804. doi:10.1021/jm020545z.
Huang MT, Chen ZX, Wei B, et al. Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. Acta Pharmacol Sin. 2007;28:1842–1850. doi:10.1111/j.1745-7254.2007.00652.x.
Cho SJ, Kim N, Kim JS, Jung HC, Song IS. The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci. 2007;52:1713–1721. doi:10.1007/s10620-007-9787-3.
Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001;15:2742–2744.
Makitie AA, Chau M, Lim S, et al. Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma. J Otolaryngol. 2003;32:226–229. doi:10.2310/7070.2003.41701.
Narayanan BA, Condon MS, Bosland MC, Narayanan NK, Reddy BS. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res. 2003;9:3503–3513.
Liao WM, Zhang CL, Li FB, Zeng BF, Zeng YX. p21WAF1/CIP1 gene DNA sequencing and its expression in human osteosarcoma. Chin Med J. 2004;117:936–940.
Matsui TA, Sowa Y, Murata H, et al. The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line. Int J Oncol. 2007;31:915–922.
Hui CM, Cheung PY, Ling MT, et al. Id-1 promotes proliferation of p53-deficient esophageal cancer cells. Int J Cancer. 2006;119:508–514. doi:10.1002/ijc.21874.
Inadomi T, Tan M, Suzuki H, Shigematsu C. Immunohistochemical evaluation of the probability of skin metastasis in gastric cancer. Eur J Dermatol. 1999;9:214–217.
Xi YG, Ding KY, Su XL, et al. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis. 2004;25:2201–2206. doi:10.1093/carcin/bgh229.
Mizokami K, Kakeji Y, Oda S, Maehara Y. Relationship of hypoxia-inducible factor 1alpha and p21WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer. World J Surg Oncol. 2006;4:94. doi:10.1186/1477-7819-4-94.
Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18:5321–5333. doi:10.1093/emboj/18.19.5321.
Narayanan BA. Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Curr Cancer Drug Targets. 2006;6:711–727. doi:10.2174/156800906779010218.
Yang H, Zhang Y, Zhao R, et al. Negative cell cycle regulator 14–3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt. Oncogene. 2006;25:4585–4594. doi:10.1038/sj.onc.1209481.
Anagnostopoulos GK, Stefanou D, Arkoumani E, et al. Bax and Bcl-2 protein expression in gastric precancerous lesions: immunohistochemical study. J Gastroenterol Hepatol. 2005;20:1674–1678. doi:10.1111/j.1440-1746.2005.04057.x.
Triantafyllou K, Kitsanta P, Karamanolis DG, Kittas C, Ladas SD. Epithelial cell turnover, p53 and bcl-2 protein expression during oncogenesis of early and advanced gastric cancer in a Western population. Dig Liver Dis. 2008;40:39–45. doi:10.1016/j.dld.2007.09.010.
Acknowledgment
This work was supported by the Youth Research Foundation of Shanghai Municipal Health Bureau.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, H., Huang, P., Xu, X. et al. Anticancer Effect of Celecoxib via COX-2 Dependent and Independent Mechanisms in Human Gastric Cancers Cells. Dig Dis Sci 54, 1418–1424 (2009). https://doi.org/10.1007/s10620-008-0510-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-008-0510-9